glp-1 compounding news november 2025 Covering Drugs: Employers' Top Questions Answered – Sequoia GLP-1 Drugs: 2025 Pulse Survey

Consumers are urged to avoid: Due to gaps in reporting requirements, adverse reactions to compounded medications are likely underreported

It is important to note that Zepbound is not approved to treat type 2 diabetes under this brand name, even though its active ingredient (tirzepatide) is used in diabetes care under a different brand name (Mounjaro)

The GLP-1 narrative has undoubtedly surpassed its beginnings

Counsel patients regarding the potential risk for MTC with the use of liraglutide injection and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness)